玻璃体腔注射克林霉素联合地塞米松、全身复方磺胺甲噁唑和类固醇治疗免疫功能正常者黄斑部弓形虫视网膜脉络膜炎的联合方案
回顾性研究纳入2014年1月至2021年12月免疫功能正常的弓形虫视网膜脉络膜炎患者39例39眼,接受口服与玻璃体腔联合治疗。最终随访时视力平均提高5行(ETDRS视力表),所有病例视网膜炎均消退。
要点
- 39眼(39例)中,视网膜炎位于中心凹24眼、中心凹外15眼,平均病灶大小1.24±0.70视盘直径。
- 平均注射次数1.79次,平均间隔1.39周,最终随访时ETDRS视力平均提高5行。
- 玻璃体腔克林霉素联合地塞米松作为全身治疗的辅助手段,所有病例视网膜炎消退且视力改善。
核心结论
- 玻璃体腔注射克林霉素联合地塞米松作为全身治疗的辅助手段,在所有病例中均显示视网膜炎消退并伴有视力改善。
研究设计与样本
- 回顾性研究,纳入2014年1月至2021年12月期间接受口服与玻璃体腔联合治疗的免疫功能正常弓形虫视网膜脉络膜炎病例,共39眼(39例)符合纳入标准。
主要发现
- 平均就诊年龄25.25岁(±9.30,范围4-52岁),男性24例(61.53%),女性15例(38.47%)。
- 活动性视网膜炎均为单侧(右眼20眼,左眼19眼),最终随访时ETDRS视力表视力提高5行。
- 视网膜炎位置为中心凹24眼或中心凹外15眼,平均病灶大小1.24±0.70视盘直径。
- 平均注射次数1.79次,平均间隔1.39周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the role of intravitreal clindamycin with dexamethasone as an adjuvant to systemic co-trimoxazole and steroids in macular Toxoplasma retinochoroiditis. METHODS: Retrospective study of Toxoplasma retinochoroiditis cases from January 2014 to December 2021 treated with a combination of oral and intravitreal therapy in immunocompetent patients. RESULTS: Thirty-nine eyes of 39 patients were included in this study after meeting the inclusion criteria with the mean age of presentation being 25.25 years (±9.30; range 4-52 years). Male preponderance with 61.53% of male patients (n = 24) and 38.47% of female patients (n = 15) was observed. Active retinitis was unilateral in all eyes (20 right eyes; 19 left eyes). Five lines of improvement in visual acuity on Early Treatment Diabetic Retinopathy Study (ETDRS) chart were noted at final visit. The location of retinitis was either foveal (n = 24) or extrafoveal (n = 15). The mean size of retinitis was 1.24 ± 0.70-disc diameter. The mean number of injections given was 1.79 with a mean interval of 1.39 weeks. CONCLUSION: Intravitreal clindamycin with dexamethasone when used as an adjunct to systemic therapy showed resolution of retinitis in all cases with visual improvement.
引用
- Satavasia S, Mishra A, Jadhav V, et al. A COMBINATION REGIMEN OF INTRAVITREAL CLINDAMYCIN WITH DEXAMETHASONE, SYSTEMIC CO-TRIMOXAZOLE AND STEROIDS FOR MACULAR TOXOPLASMA RETINOCHOROIDITIS IN IMMUNOCOMPETENT CASES. Retina. 2025. PMID: 39813301. doi:10.1097/IAE.0000000000004383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。